DengiAll will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027
Panacea Biotec receives acceptance from CMSS for supply of bOPV
Panacea Biotec receives Rs. 315 crore LoA from UNICEF
Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension
Ami Organics’ Ankleshwar Unit II gets GMP compliant by PMDA Japan
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
The clinical trial will be conducted at 19 sites with 10,335 participants across India
Receives registration of Valganciclovir powder for oral solution in Germany
Subscribe To Our Newsletter & Stay Updated
